Cedar Brook Financial Partners’s Royalty Pharma RPRX Stock Holding History

Cedar Brook Financial Partners’s Portfolio RPRX Stock Details RPRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-5,000	Closed	-$201K	–	384
2022 Q3	$201K	Hold	5,000	–	–	0.06%	329
2022 Q2	$210K	Buy	+5,000	New	+$205K	0.07%	315
2021 Q3	–	Sell	-5,000	Closed	-$205K	–	371
2021 Q2	$205K	Hold	5,000	–	–	0.06%	352
2021 Q1	$218K	Hold	5,000	–	–	0.08%	294
2020 Q4	$250K	Buy	+5,000	New	+$212K	0.09%	254

Other funds holding RPRX

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Cedar Brook Financial Partners's RPRX Position: Q4 2022 in Review

Cedar Brook Financial Partners sold out of Royalty Pharma (RPRX) in Q4 2022, closing a stake of 5,000 shares — an estimated $201K sold.

Cedar Brook Financial Partners first reported a position in RPRX in Q4 2020 and held it in 5 quarters. The position peaked at $250K in Q4 2020. 334 funds tracked by Wall St. Rank hold RPRX as of Q4 2022.

Cedar Brook Financial Partners reported no remaining Royalty Pharma position as of Q4 2022 after selling out during the quarter.
Cedar Brook Financial Partners sold 5,000 Royalty Pharma shares in Q4 2022, an estimated $201K.
Cedar Brook Financial Partners first reported a position in Royalty Pharma in Q4 2020 and held it in 5 quarters.
Cedar Brook Financial Partners's Royalty Pharma position peaked at $250K in Q4 2020.
334 funds tracked by Wall St. Rank held Royalty Pharma as of Q4 2022.

Based on Cedar Brook Financial Partners's 13F filing for Q4 2022, filed 1 Feb 2023.